BCS Financial has expanded its stop loss and reinsurance offerings to include new payer solutions in response to the growing gene therapy pipeline.
Peter Costello, BCS President & Chief Executive Officer, commented, “Gene therapies offer the promise of potential cures, but with treatment costs ranging from $2m to $4m payers and self-insured employers will be challenged to finance these unprecedented costs.
“At BCS, we are focused on finding new ways to help health plans, employers, and ultimately insureds finance and utilize these costly treatments as part of our mission to improve affordability and access to care.”
